Lab Information
Sasha Bernatsky (MD/PhD)
Senior ScientistCentre for Outcomes Research and Evaluation
Department of Medicine (McGill)
Research Profile
Keywords
Pharmacoepidemiology • systemic lupus • rheumatic disease • drug safety and effectiveness • air pollutionResearch Interests
My research focuses mainly on outcomes in rheumatic diseases, pharmacoepidemiology, and air pollution’s effects on health.Team Members
| Name | Position |
|---|
Latest Publications
- Tan, J., Bernatsky, S., Lee, J. L. F., Fortin, P. R., Dayam, R. M., Gingras, A.-C., Colmegna, I., Bowdish, D. M. E., Berger, C., Chan, D., Larché, M. J., Richards, D. P., Gonzalez Arreola, L., Hitchon, C. A., Lalonde, N. & Aviña-Zubieta, J. A. (2025). COVID-19 Breakthrough Infections in Immune-Mediated Inflammatory Diseases: Data from the SUCCEED (Safety and Immunogenicity of COVID-19 Vaccines in Systemic Autoimmune-Mediated Inflammatory Diseases) Study. Vaccines, vol. 13.
- Krustev, E., Fritzler, M. J., Bernatsky, S., St Pierre, Y., Sciore, P. J., Vinet, E., Pineau, C. A., Mendel, A., Kalache, F., Grenier, L.-P., Cotton, T., Niaki, O. Z. & Choi, M. Y. (2025). Anti-myxovirus resistance protein 1: a novel biomarker for autoimmune myositis and interstitial lung disease in systemic lupus erythematosus. Annals of the rheumatic diseases.
- Stanciu, M., Lee, J.-E., McDonald, E. G., Clark, G., Pineau, C. A., Kalache, F., Grenier, L.-P., Vinet, É., Bernatsky, S. & Mendel, A. (2025). Medication-related hospitalisations in patients with SLE. Lupus science & medicine, vol. 12.
- Birck, M. G., Moura, C. S., Winthrop, K. L., Machado, M. A. A., Neville, A. & Bernatsky, S. (2025). Choosing Wisely: Effectiveness and Safety of Antibiotic Prophylaxis in Close Contacts of Invasive Group A Streptococci Infection. Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, vol. 80, p. 314-315.
- Birck, M. G., Lukusa, L., Choquette, D., Boire, G., Maksymowych, W. P., Singh, H., Afif, W. & Bernatsky, S. (2024). Incidence of serious infection among etanercept and infliximab initiators: safety comparison between biosimilars and bio-originators with Canadian population-based data. BMC rheumatology, vol. 8, p. 47.
- Hitchon, C. A., Bowdish, D. M. E., Boire, G., Fortin, P. R., Flamand, L., Chandran, V., Dayam, R. M., Gingras, A.-C., Card, C. M., Colmegna, I., Larché, M. J., Kaplan, G. G., Lukusa, L., Lee, J. L. F., Bernatsky, S. & (2024). Methotrexate and Tumor Necrosis Factor Inhibitors Independently Decrease Neutralizing Antibodies after SARS-CoV-2 Vaccination: Updated Results from the SUCCEED Study. Vaccines, vol. 12.
- Tsyruk, O., Kaplan, G. G., Fortin, P. R., Hitchon, C. A., Chandran, V., Larché, M. J., Avina-Zubieta, A., Boire, G., Colmegna, I., Lacaille, D., Lalonde, N., Proulx, L., Richards, D. P., Boivin, N., DeBow, C., Kovalova-Wood, L., Paleczny, D., Wilhelm, L., Lukusa, L., Pereira, D., Lee, J. L., Bernatsky, S. & (2024). How Safe Are COVID-19 Vaccines in Individuals with Immune-Mediated Inflammatory Diseases? The SUCCEED Study. Vaccines, vol. 12.
- Bernatsky, S. (2024). Dr. Bernatsky replies. The Journal of rheumatology, vol. 51, p. 1150.
- Mendel, A., Behlouli, H., Vinet, É., Curtis, J. R. & Bernatsky, S. (2024). Trimethoprim sulfamethoxazole prophylaxis and serious infections in granulomatosis with polyangiitis treated with rituximab. Rheumatology (Oxford, England).
- Zhao, N., Smargiassi, A., Chen, H., Widdifield, J. & Bernatsky, S. (2025). Fine particulate matter components and risk of rheumatoid arthritis: A large general Canadian open cohort study. Arthritis care & research, vol. 77, p. 15-22.
See also
